Evidence of organ damage after cardiopulmonary bypass. The role of elastase and vasoactive mediators.
In this study the causes of organ damage after cardiopulmonary bypass were multifactorial. The concentration of the proteolytic enzyme elastase, which was released from activated granulocytes in the milieu of significantly reduced levels of alpha 1-protease inhibitor (p less than 0.01), increased during cardiopulmonary bypass (p less than 0.01). In addition, bypass initiated platelet aggregation, which both altered the eicosanoid metabolism and caused the level of thromboxane A2 to increase and surpass the level of prostaglandin I2. Because thromboxane A2 dominance subsided immediately after cardiopulmonary bypass, the effect of thromboxane A2 (vasoconstriction) on the development of organ damage may have been influential only during bypass. Both during and after bypass, the increase in endothelin excretion (p less than 0.01 to 0.05) was believed to induce a further vasoconstriction in the microvasculature. On completion of the cardiopulmonary bypass, the elevation of the lysosomal enzyme beta-glucuronidase, which is a sensitive indicator of cellular damage, was influenced by the concentrations of elastase (r = 0.8) and endothelin (r = 0.52). As evidenced by leuko-sequestration in the lung after cardiopulmonary bypass, the increase in the alveolar-arterial oxygen tension difference correlated with the elastase concentration (r = 0.68). Renal damage, which was detected by an increase in renal tubular enzymes (N-acetyl-beta-D-glucosaminidase and gamma-glutamyltranspeptidase) was affected by the endothelin (r = 0.68, 0.56) and elastase levels (r = 0.58, 0.68), respectively, but not by the ratio of thromboxane B2 to prostaglandin F1 alpha. The elastase level influenced the pulmonary vascular resistance (r = 0.56). However, neither the cardiac index nor the systemic and pulmonary vascular resistances were influenced by the endothelin level and the ratio of thromboxane B2 to prostaglandin F1 alpha.
Hashimoto
K
K
Department of Cardiovascular Surgery, Jikei University School of Medicine, Tokyo, Japan.
Miyamoto
H
H
Suzuki
K
K
Horikoshi
S
S
Matsui
M
M
Arai
T
T
Kurosawa
H
H
D000118:Acetylglucosaminidase / Q000032:analysis; D000328:Adult; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D016232:Endothelins / Q000502:physiology*; D005260:Female; D005966:Glucuronidase / Q000032:analysis; D006439:Hemodynamics; D006801:Humans; D007684:Kidney Tubules / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D010196:Pancreatic Elastase / Q000502:physiology*; D011460:Prostaglandins F / Q000502:physiology; D012119:Respiration; D013928:Thromboxane A2 / Q000502:physiology*; D013929:Thromboxane B2 / Q000502:physiology; D005723:gamma-Glutamyltransferase / Q000032:analysis
D016232:Endothelins; D011460:Prostaglandins F; D013929:Thromboxane B2; D013928:Thromboxane A2; D005723:gamma-Glutamyltransferase; D005966:Glucuronidase; D000118:Acetylglucosaminidase; D010196:Pancreatic Elastase; C100006:prostaglandin F1